Castle Biosciences Inc. (CSTL) said it expects to meet or exceed the top end of its full-year 2024 revenue guidance of $320 million - $330 million. The achievement reflects its commitment to delivering value to its stockholders while advancing its mission of improving health through innovative tests that guide patient care.
The company said it delivered 24,071 total test reports in the fourth quarter of 2024, compared to 20,284 in the same period of 2023.
The company delivered 96,071 total test reports in 2024, compared to 70,429 in the same period of 2023.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.